Mpumalanga: The launch of Lenacapavir - a groundbreaking HIV drug - will be held on June 5 in Mpumalanga. According to South African Government News Agency, Health Minister Dr. Aaron Motsoaledi delivered the department's budget vote on Wednesday, announcing that Lenacapavir will be available soon. Lenacapavir is administered via injection twice a year, offering patients six months of continuous protection per dose. This presents a significant shift from daily pills or bi-monthly injections. Dr. Motsoaledi stated, "In the next two weeks, we will be delivering Lenacapavir stocks to depots and health facilities. We will be starting with 360 health facilities in the high burden districts of the country." The prioritization for receiving Lenacapavir includes adolescent girls and young women up to age 24, pregnant and breastfeeding mothers, female sex workers, men-having-sex-with-men, transgender people, and injecting drug users. Dr. Motsoaledi expressed optimism about South Africa's fight against HIV, suggest ing the country is on the path to eliminating it as a public health threat. He highlighted South Africa's achievements, such as increased life expectancy and reduced maternal and under-5 mortality rates. In addition to the HIV initiatives, Dr. Motsoaledi addressed the growing concern of cervical cancer in South Africa, describing it as the "new HIV pandemic." He introduced the WHO's 90-70-90 formula to combat cervical cancer and explained South Africa's adaptation of this strategy due to the high HIV/AIDS burden. The country has extended the age cohort for screening and treatment to better address the overlap of HIV and cervical cancer.